Mabwell (Shanghai) Bioscience
Mabwell (Shanghai) Bioscience is a China-based biotechnology company running 11 late-stage cancer trials of Toripalimab (JS001 ) and JS207 in bladder & urothelial cancer, cervical cancer and colorectal cancer.
Overview
Mabwell (Shanghai) Bioscience, based in Shanghai, China, is a biotechnology company listed as 688062.SH, 02493.HK. Mabwell is an innovation-driven biopharmaceutical company covering the full chain of antibody drug research, manufacturing and commercialisation, with several marketed monoclonal antibody and biosimilar products. On ClinicalTrials.gov it is the lead sponsor of 11 recruiting or active phase 2 and phase 3 interventional cancer trials (3 in phase 3), testing Toripalimab (JS001 ) and JS207 in bladder & urothelial cancer, cervical cancer, colorectal cancer and triple-negative breast cancer. The largest, NCT06592326 (9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer), plans to enrol 460 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry, checked on 2026-09-11; company facts are from the official website.
Similar pages
not linked directly; found by shared links- CompanySuzhou Forlong Biotechnology
Shares Bladder & urothelial cancer and the tag ctgov-sponsor.
- CompanyBio-Thera Solutions
Shares Cervical cancer and the tag ctgov-sponsor.
- CompanySTCube
Shares Colorectal cancer and the tag ctgov-sponsor.
- CompanyNeonc Technologies
Shares Cervical cancer, Colorectal cancer and the tag ctgov-sponsor.
- CompanyMultitude Therapeutics
Shares Colorectal cancer and the tag ctgov-sponsor.
- CompanyTiumBio
Shares Colorectal cancer and the tag ctgov-sponsor.
- CompanyShanghai Kechow Pharma
Shares Colorectal cancer and the tag ctgov-sponsor.
- CompanyMolecular Partners
Shares Bladder & urothelial cancer and the tag ctgov-sponsor.